An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.

Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently read X-ray images and detect bone fractures, or assess cancer tumors in both ...

A prostate biopsy is a procedure to remove small samples of tissue from the prostate gland. It's a method to test for prostate cancer if a prostate-specific antigen (PSA) blood test or digital rectal ...

The MarketWatch News Department was not involved in the creation of this content. GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", ...

In a biopsy, a small sample of tissue is taken from your body. A pathologist analyzes the sample to check for cancer cells. The main method for diagnosing prostate cancer is a core needle biopsy. It’s ...

Digital Health News: Daniel Spratt, chair of radiation oncology at Case Comprehensive Cancer Center, commented on a new AI-enabled prostate cancer risk assessment tool has been developed to analyze ...

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

More than 2 million prostate biopsies are performed annually in the USA and Europe, but there is debate over the optimal approach. The procedural time is shorter for transrectal (TR) than for ...

Our study found that PZ biopsies offer no additional benefit for TZ lesion tumors, and increasing the number of cores in the TZ region can compensate for the current limitations of TZ biopsies. These ...